| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Over the last 12 months, insiders at Oramed Pharmaceuticals Inc. have bought $0 and sold $0 worth of Oramed Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Oramed Pharmaceuticals Inc. have bought $415,102 and sold $1.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,800 shares for transaction amount of $8,398 was made by Mayer Arie (director) on 2023‑04‑04.
| 2023-04-04 | Mayer Arie | director | 3,800 0.01% | $2.21 | $8,398 | +30.85% | ||
| 2023-04-03 | Mayer Arie | director | 5,009 0.0129% | $2.22 | $11,120 | +27.67% | ||
| 2023-03-16 | KIDRON NADAV | President and CEO | 26,000 0.0615% | $2.04 | $53,014 | +24.27% | ||
| 2023-03-14 | Sale | Kidron Miriam | Chief Scientific Officer | 100,000 0.2466% | $2.01 | $201,000 | +29.74% | |
| 2023-03-14 | KIDRON NADAV | President and CEO | 100,000 0.2466% | $2.01 | $201,000 | +29.74% | ||
| 2023-03-14 | Rozov Yadin | director | 50,000 0.1257% | $2.05 | $102,450 | +29.74% | ||
| 2023-03-13 | Rozov Yadin | director | 20,000 0.0499% | $1.96 | $39,120 | +35.29% | ||
| 2023-01-03 | Sale | Rabinowitz Michael | Chief Commercial Officer | 13,325 0.0346% | $12.55 | $167,195 | -81.40% | |
| 2022-03-21 | Sale | RAKIN KEVIN | 10,000 0.0258% | $9.41 | $94,096 | -28.70% | ||
| 2021-11-01 | Sale | Mayer Arie | director | 3,000 0.0084% | $25.60 | $76,800 | -65.70% | |
| 2021-09-16 | Sale | RAKIN KEVIN | director | 21,100 0.0579% | $20.99 | $442,830 | -55.96% | |
| 2021-08-09 | Sale | KIDRON NADAV | President and CEO | 220,000 0.7367% | $20.11 | $4.42M | -50.46% | |
| 2019-09-09 | Sank Leonard | director | 50,000 0.2901% | $2.92 | $146,000 | +20.52% | ||
| 2019-07-18 | Sank Leonard | director | 8,994 0.0501% | $3.85 | $34,672 | -15.72% | ||
| 2019-07-17 | Sank Leonard | director | 60,040 0.3268% | $3.63 | $218,118 | -12.64% | ||
| 2019-07-16 | Sank Leonard | director | 40,000 0.2278% | $3.52 | $140,878 | -5.76% | ||
| 2019-07-11 | Sank Leonard | director | 2,640 0.0147% | $3.22 | $8,501 | +0.97% | ||
| 2018-08-09 | Friedman Aviad | director | 5,000 0.029% | $4.95 | $24,740 | -25.88% | ||
| 2018-07-11 | KIDRON NADAV | President and CEO | 244 0.0014% | $5.92 | $1,444 | -36.76% | ||
| 2018-07-10 | Sale | KIDRON NADAV | President and CEO | 122 0.0007% | $5.98 | $730 | -36.67% |
| Bronfeld Zeev | 10 percent owner | 5808517 14.5766% | $18.59M | 1 | 1 | |
| REGALS CAPITAL MANAGEMENT LP | 10 percent owner | 1453637 3.6479% | $4.65M | 7 | 0 | <0.0001% |
| Sank Leonard | director | 374999 0.9411% | $1.2M | 12 | 0 | +53.27% |
| Li Xiaopeng | director | 206350 0.5178% | $660,320.00 | 2 | 0 | +13.29% |
| Kidron Miriam | Chief Scientific Officer | 201666 0.5061% | $645,331.20 | 0 | 10 | |
| Rabinowitz Michael | Chief Commercial Officer | 126143 0.3166% | $403,657.60 | 0 | 1 | |
| KIDRON NADAV | President and CEO | 126000 0.3162% | $403,200.00 | 7 | 2 | +24.34% |
| Rozov Yadin | director | 86500 0.2171% | $276,800.00 | 2 | 0 | +32.52% |
| RAKIN KEVIN | 46661 0.1171% | $149,315.20 | 0 | 2 | ||
| Mayer Arie | director | 26809 0.0673% | $85,788.80 | 2 | 1 | +29.26% |
| Berelowitz Michael | director | 22896 0.0575% | $73,267.20 | 0 | 4 | |
| JACOB HAROLD | director | 16396 0.0411% | $52,467.20 | 1 | 2 | <0.0001% |
| Friedman Aviad | director | 12191 0.0306% | $39,011.20 | 1 | 0 | <0.0001% |
| Young Michael | 0 0% | $0 | 0 | 1 |
$17,525,882 | 60 | 5.22% | $108.63M | |
$6,861,925 | 44 | 8.31% | $109.29M | |
$48,218,096 | 42 | 0.89% | $124.5M | |
$16,259,194 | 41 | 120.51% | $130.59M | |
Oramed Pharmaceuticals Inc. (ORMP) | $7,147,964 | 34 | 24.77% | $127.51M |
$167,701,902 | 27 | -3.07% | $116.44M | |
$178,593,887 | 15 | -14.86% | $127.05M | |
$448,999,793 | 15 | -19.99% | $146.32M | |
$156,530,514 | 13 | 45.71% | $123.07M | |
$15,799,576 | 12 | -39.52% | $126.49M | |
$13,919,584 | 9 | -30.43% | $144.79M | |
$2,762,881 | 8 | -10.76% | $119.99M | |
$99,355,998 | 7 | -65.74% | $148.4M | |
$22,090,972 | 7 | -3.49% | $132.4M | |
$68,692,148 | 6 | -39.10% | $115.32M | |
$299,343 | 6 | -44.75% | $144.88M | |
$20,729,984 | 5 | 51.71% | $141.72M | |
$556,839 | 5 | 13.42% | $130.25M | |
$13,001,183 | 5 | 58.75% | $154.5M |
| Increased Positions | 19 | +35.85% | 451,331 | +4.89% |
| Decreased Positions | 17 | -32.08% | 98,144 | -1.06% |
| New Positions | 6 | New | 333,876 | New |
| Sold Out Positions | 8 | Sold Out | 11,688 | Sold Out |
| Total Postitions | 55 | +3.77% | 10M | +3.83% |
| Bml Capital Management, Llc | $9,217.00 | 7.92% | 3.17M | +83,978 | +2.72% | 2025-09-30 |
| Murchinson Ltd. | $5,097.00 | 4.38% | 1.75M | 0 | 0% | 2025-09-30 |
| Boothbay Fund Management, Llc | $2,460.00 | 2.11% | 845,391 | 0 | 0% | 2025-09-30 |
| Rathbones Group Plc | $678.00 | 0.58% | 233,018 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $436.00 | 0.37% | 149,667 | +6,261 | +4.37% | 2025-09-30 |
| Renaissance Technologies Llc | $433.00 | 0.37% | 148,900 | +4,700 | +3.26% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $429.00 | 0.37% | 147,487 | -19,412 | -11.63% | 2025-09-30 |
| Wells Fargo & Company/Mn | $379.00 | 0.33% | 130,086 | +109,100 | +519.87% | 2025-09-30 |
| Citadel Advisors Llc | $325.00 | 0.28% | 111,707 | +24,391 | +27.93% | 2025-09-30 |
| Blackrock, Inc. | $319.00 | 0.27% | 109,733 | +24,163 | +28.24% | 2025-09-30 |